TY - JOUR
T1 - Metabolic, cardiovascular, and substance use evaluation of living kidney donor candidates
T2 - US practices in 2017
AU - Garg, Neetika
AU - Lentine, Krista L.
AU - Inker, Lesley A.
AU - Garg, Amit X.
AU - Rodrigue, James R.
AU - Segev, Dorry L.
AU - Mandelbrot, Didier A.
N1 - Funding Information:
The authors of this manuscript have conflicts of interest to disclose as described by the . KLL receives funding related to living donation research from the National Institutes of Health (U01‐DK116042 and R01DK120551). LAI reports funding from Tufts Medical Center for research and contracts with the National Institutes of Health, National Kidney Foundation, Retrophin, Omeros, and Reata Pharmaceuticals. She has consulting agreements with Tricida Inc and Omeros Corp. JRR is supported by Award No. R01DK114877 from the National Institute of Diabetes and Digestive and Kidney Diseases and Award No. R39OT29876 from the Health Resources and Services Administration. AXG was supported by the Dr Adam Linton Chair in Kidney Health Analytics, and a Clinician Investigator Award from the Canadian Institutes of Health Research. NG, DLS, and DAM have no relevant disclosures to disclose. American Journal of Transplantation
Funding Information:
DAM is the recipient of an unrestricted research grant from the Virginia Lee Cook Foundation, funds from which were used to conduct this study.
Publisher Copyright:
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons
PY - 2020/12
Y1 - 2020/12
N2 - We surveyed US transplant centers to assess practices regarding the evaluation and selection of living kidney donors based on metabolic, cardiovascular, and substance use risk factors. Our companion article describes renal aspects of the evaluation. Response rate was 31%. Compared with 2005, programs have become more accepting of hypertensive candidates: 65% in 2017% vs 41% in 2005 consider candidates with hypertension well controlled with 1 medication. One notable exception is black hypertensive candidates, who are frequently excluded regardless of severity. The most common body mass index (BMI) cutoff remains 35 kg/m2, and fewer programs now consider candidates with BMI >40 kg/m2. A 2-hour oral glucose tolerance test of ≥140 mg/dL remains the most common criterion for exclusion of prediabetic candidates. One quarter to one third of programs exclude based on isolated cardiac abnormalities, such as mild aortic stenosis; a similar proportion consider these candidates only if older than 50 years. Cigarette or marijuana smoking are infrequently criteria for exclusion, although 45% and 37% programs, respectively, require cessation 4 weeks prior to surgery. In addition to providing an overview of current practices in living kidney donor evaluation, our study highlights the importance of research evaluating outcomes with various comorbidities to guide practice.
AB - We surveyed US transplant centers to assess practices regarding the evaluation and selection of living kidney donors based on metabolic, cardiovascular, and substance use risk factors. Our companion article describes renal aspects of the evaluation. Response rate was 31%. Compared with 2005, programs have become more accepting of hypertensive candidates: 65% in 2017% vs 41% in 2005 consider candidates with hypertension well controlled with 1 medication. One notable exception is black hypertensive candidates, who are frequently excluded regardless of severity. The most common body mass index (BMI) cutoff remains 35 kg/m2, and fewer programs now consider candidates with BMI >40 kg/m2. A 2-hour oral glucose tolerance test of ≥140 mg/dL remains the most common criterion for exclusion of prediabetic candidates. One quarter to one third of programs exclude based on isolated cardiac abnormalities, such as mild aortic stenosis; a similar proportion consider these candidates only if older than 50 years. Cigarette or marijuana smoking are infrequently criteria for exclusion, although 45% and 37% programs, respectively, require cessation 4 weeks prior to surgery. In addition to providing an overview of current practices in living kidney donor evaluation, our study highlights the importance of research evaluating outcomes with various comorbidities to guide practice.
KW - Clinical research/practice
KW - Donors and donation: donor evaluation
KW - Donors and donation: living
KW - Hypertension/antihypertensives
KW - United Network for Organ Sharing (UNOS)
KW - kidney transplantation/nephrology
UR - http://www.scopus.com/inward/record.url?scp=85085055114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085055114&partnerID=8YFLogxK
U2 - 10.1111/ajt.15964
DO - 10.1111/ajt.15964
M3 - Article
C2 - 32342601
AN - SCOPUS:85085055114
SN - 1600-6135
VL - 20
SP - 3390
EP - 3400
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 12
ER -